Avadel Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Avadel Pharmaceuticals's earnings have been declining at an average annual rate of -32.2%, while the Pharmaceuticals industry saw earnings growing at 4.9% annually. Revenues have been declining at an average rate of 20.7% per year.
Key information
-32.2%
Earnings growth rate
-16.1%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -20.7% |
Return on equity | -151.1% |
Net Margin | -111.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Avadel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 95 | -106 | 176 | 12 |
31 Mar 24 | 55 | -157 | 176 | 12 |
31 Dec 23 | 28 | -160 | 152 | 13 |
30 Sep 23 | 9 | -159 | 127 | 17 |
30 Jun 23 | 1 | -143 | 102 | 17 |
31 Mar 23 | 0 | -142 | 77 | 18 |
31 Dec 22 | 0 | -137 | 75 | 21 |
30 Sep 22 | 0 | -132 | 79 | 17 |
30 Jun 22 | 0 | -134 | 86 | 18 |
31 Mar 22 | 0 | -90 | 79 | 20 |
31 Dec 21 | 0 | -77 | 68 | 17 |
30 Sep 21 | 0 | -66 | 56 | 20 |
30 Jun 21 | 0 | -56 | 44 | 21 |
31 Mar 21 | 10 | -6 | 36 | 19 |
31 Dec 20 | 22 | 7 | 32 | 20 |
30 Sep 20 | 33 | 16 | 31 | 23 |
30 Jun 20 | 48 | 18 | 28 | 25 |
31 Mar 20 | 55 | -21 | 28 | 31 |
31 Dec 19 | 59 | -33 | 30 | 33 |
30 Sep 19 | 69 | -94 | 46 | 31 |
30 Jun 19 | 75 | -101 | 65 | 35 |
31 Mar 19 | 86 | -96 | 86 | 37 |
31 Dec 18 | 103 | -95 | 100 | 39 |
30 Sep 18 | 117 | -40 | 101 | 66 |
30 Jun 18 | 137 | -2 | 88 | 54 |
31 Mar 18 | 154 | 30 | 73 | 42 |
31 Dec 17 | 173 | 68 | 59 | 33 |
30 Sep 17 | 182 | 81 | 46 | 0 |
30 Jun 17 | 174 | 40 | 48 | 0 |
31 Mar 17 | 167 | -9 | 47 | 0 |
31 Dec 16 | 150 | -41 | 45 | 34 |
30 Sep 16 | 152 | 28 | 40 | 0 |
30 Jun 16 | 167 | 19 | 32 | 0 |
31 Mar 16 | 177 | 23 | 27 | 0 |
31 Dec 15 | 173 | 42 | 22 | 0 |
30 Sep 15 | 127 | -64 | 19 | 0 |
30 Jun 15 | 87 | -46 | 18 | 0 |
31 Mar 15 | 43 | -49 | 17 | 0 |
31 Dec 14 | 15 | -89 | 16 | 0 |
30 Sep 14 | 4 | -56 | 17 | 0 |
30 Jun 14 | 2 | -52 | 16 | 0 |
31 Mar 14 | 4 | -65 | 14 | 0 |
31 Dec 13 | 4 | -47 | 13 | 0 |
30 Sep 13 | 24 | -39 | 10 | 0 |
Quality Earnings: AWK is currently unprofitable.
Growing Profit Margin: AWK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AWK is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.
Accelerating Growth: Unable to compare AWK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AWK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: AWK has a negative Return on Equity (-151.13%), as it is currently unprofitable.